Skip to main content
. 2011 Dec 30;17(1):80–90. doi: 10.1634/theoncologist.2011-0177

Table 2.

High-dose chemotherapy regimens used with autologous stem cell transplantation

graphic file with name onc00112-0961-t02.jpg

aOverall percentage of toxic deaths, including patients transplanted by infusion of bone marrow. TRM for patients transplanted with peripheral blood stem cells, 1.3%.

bFive-year cumulative incidence of secondary malignancies, 4.3%.

cTRM at 100 days after transplant; 8-year actuarial risk for secondary malignancies, 9%.

dTRM at 100 days after transplant; 10-year cumulative probability of developing a secondary malignancy, 17%.

Abbreviations: BEAC, carmustine, etoposide, cytarabine, and cyclophosphamide; BEAM, carmustine, etoposide, cytarabine, and melphalan; BeEAM, bendamustine, etoposide, cytarabine, and melphalan; BuCyE, busulfan, cyclophosphamide, and etoposide; BuMel, busulfan and melphalan; CBV, cyclophosphamide, carmustine, and etoposide; CBVP, cyclophosphamide, carmustine, etoposide, and cisplatin; CCV, carmustine, cyclophosphamide, and etoposide; CV, cyclophosphamide and etoposide; CVP, cyclophosphamide, etoposide, and a platinum; GemBuMel, gemcitabine, busulfan, and melphalan; LACE, lomustine, cytarabine, cyclophosphamide, and etoposide; NS, not stated; OS, overall survival; PFS, progression-free survival; SHDCT, sequential high-dose chemotherapy; TBI, total body irradiation; TLI, total lymphoid irradiation; TRM, treatment-related mortality; VCB, etoposide, cyclophosphamide, and carmustine.